Thermo Fisher, Cynvenio Ink Distribution Agreement for LiquidBiopsy Platform | GenomeWeb

NEW YORK (GenomeWeb) – Thermo Fisher Scientific and Cynvenio Biosystems have signed a distribution agreement for Cynvenio's LiquidBiopsy platform, the companies said today.

Cynvenio's LiquidBiopsy platform is designed to extract and isolate circulating tumor cells from a blood draw and prepare them for imaging and genomic analysis. According to Cynvenio's website, the platform uses a patented microfluidic chip to recover tumor cells from whole blood and can process up to four samples in under three hours.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.